已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SciGPT的应助被CLAY采纳,获得10
1秒前
Jasper的应助被CLAY采纳,获得10
2秒前
2秒前
3秒前
5秒前
5秒前
6秒前
璐璇发布了新的文献求助10
7秒前
8秒前
Kevin完成签到,获得积分10
8秒前
初景发布了新的文献求助10
8秒前
菜菜菜完成签到,获得积分10
9秒前
白芷发布了新的文献求助10
10秒前
miuwu发布了新的文献求助10
10秒前
旭一凡发布了新的文献求助50
11秒前
11秒前
12秒前
生殖吴彦祖完成签到,获得积分10
12秒前
李健的小迷弟的应助被sunyangcun采纳,获得10
12秒前
anyanjiao发布了新的文献求助10
12秒前
Ara完成签到,获得积分10
13秒前
先从这次不能完成签到,获得积分10
13秒前
jianglan完成签到,获得积分10
13秒前
无花果的应助被亓天大圣采纳,获得10
13秒前
O已w时o完成签到 ,获得积分10
13秒前
033发布了新的文献求助10
13秒前
Berry完成签到 ,获得积分10
15秒前
15秒前
天天快乐的应助被火星上彩虹采纳,获得10
17秒前
qq发布了新的文献求助10
17秒前
17秒前
17秒前
豆子发布了新的文献求助10
18秒前
18秒前
田様的应助被anyanjiao采纳,获得10
19秒前
三金发布了新的文献求助10
21秒前
21秒前
22秒前
23秒前
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Das Matthäusevangelium: Kapitel 1:1–17 1000
IRTSD: Open-Source Data and Toolset for Electromagnetic Transient Analysis of Disturbances and IBR Control Malfunctions in Transmission Systems 1000
Les Mots du discours 600
A Consideration on Use of Material Grades for Hull Structural Members Based on Fracture Toughness(Second Report) 500
AI Disclosure in Annual Reports: Evolution, Determinants, and Capital Market Participants’ Perceptions 500
5th World Conference on Detergents: Reinventing the Industry : Opportunities and Challenges 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8114641
求助须知:如何正确求助?哪些是违规求助? 9520969
关于积分的说明 21531985
捐赠科研通 7692502
什么是DOI,文献DOI怎么找? 3413224
关于科研通互助平台的介绍 2539599
邀请新用户注册赠送积分活动 2453342